Avaliku tegevuse koordineerimiskava

Avaliku tegevuse koordineerimiskava

Avaliku tegevuse koordineerimiskava

The public activities coordination tool (PACT) provides an overview of the substance-specific activities that authorities are working on under REACH and the CLP Regulation. These activities are being carried out in line with ECHA’s Integrated Regulatory Strategy.

PACT provides up-to-date information on the activities planned, ongoing or completed by ECHA and/or MSCAs for a given substance in the following areas:

  • Data generation and assessment – dossier evaluation, substance evaluation, informal hazard assessment (PBT/vPvB/ED).
  • Assessment of regulatory needs (ARN).
  • Regulatory risk management – harmonised classification and labelling (CLH) , SVHC identification, restriction.

A summary of all the substance-specific activities can be found under ‘Details’ for each entry.

PACT

1,2,4-triazole

EC / List no: 206-022-9 CAS no: 288-88-0
Data generation and assessment
DEv - Dossier evaluation
DEv 1
Scope
Testing Proposal
Status
Concluded
Decision date
15/04/2019
Decision
Latest update
07/05/2021
More information View
DEv 2
Scope
Targeted
Status
Concluded
Decision date
Decision
Latest update
07/05/2021
More information View
SEv - Substance evaluation (Community Rolling Action Plan (CoRAP))
SEv 1
Evaluating Member State
Belgium
Co-Evaluating Member State
Initial grounds for concern
Suspected CMR
Other hazard based concern
Exposure of environment
High (aggregated) tonnage
Other exposure/risk based concern
Wide dispersive use
Year
2015
Status
Concluded
Conclusion document
Latest update
14/04/2021
More information View
ED - Endocrine disruptor assessment
ED 1
Authority
Belgium
Status
Postponed
Outcome
postponed
Follow-up
No suggestion yet
Hazard assessment outcome document
Remarks
Due to the change of the registration dossier scope to intermediate use only, eMSCA concluded that at this moment further testing request to clarify concerns related to endocrine disruption is no longer justified. However the endocrine disruption potential of 1,2,4-triazole, an intrinsic property of a substance, remains unanswered and should be further investigated once there is a change in the scope of the dossier or if new information regarding this endpoint becomes available. Further information is available in the Substance Evaluation conclusion document.
Concern
Endocrine disruption
Date of intention
29/04/2015
Date of hazard assessment
Latest update
26/05/2021
More information View
Regulatory risk management
CLH - Harmonised classification and labelling
CLH 1
Status
Opinion Adopted
Date of intention
15/06/2017
Withdrawal date
Submitter
Belgium
Proposed harmonised classification by the dossier submitter
Acute Tox. 4, H302
Eye Irrit. 2, H319
Repr. 1B, H360FD
Remarks
Date of opinion
15/03/2019
RAC Opinion
Latest update
11/03/2020
More information View

Export search results to:

EU Privacy Disclaimer

This website uses cookies to ensure you get the best experience on our websites.